Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 5/20 | 0.42 |
| ▸ | ATXN2 | Q99700 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | PLD2 | O14939 | 2/20 | 0.39 |
| ▸ | PLD1 | Q13393 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 2/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL356383 | 0.88 | ENPP2 (0.49) | ENPP2ATXN2ALDH1A1DRD2HTR1A | |
| SCHEMBL354967 | 0.86 | ENPP2 (0.58) | ENPP2ATXN2KMT2AKCNH2 | |
| SCHEMBL355797 | 0.80 | ENPP2 (0.49) | ENPP2ATXN2KMT2AKCNH2CD274 | |
| SCHEMBL117414 | 0.80 | ENPP2 (0.46) | ENPP2ATXN2KMT2A | |
| SCHEMBL118452 | 0.80 | ENPP2 (0.46) | ENPP2ATXN2KMT2A | |
| SCHEMBL16240046 | 0.78 | KMT2A (0.48) | HTR1AKMT2APOLB | |
| SCHEMBL10102917 | 0.78 | ACKR3 (0.52) | DRD2HTR1AKMT2ACD274 | |
| SCHEMBL146733 | 0.77 | ENPP2 (0.43) | ENPP2ATXN2ALDH1A1 | |
| SCHEMBL357528 | 0.76 | NAMPT (0.47) | ALDH1A1HTR1AKMT2AMAOAMAOB | |
| SCHEMBL356847 | 0.75 | L3MBTL1 (0.52) | ENPP2ATXN2ALDH1A1HTR1AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2414327-B1 | HETEROCYCLIC COMPOUNDS AS AUTOTAXIN INHIBITORS | MERCK PATENT GMBH (DE) | 2014-11-19 | — | — | EP | claimed |
| US-8841324-B2 | Heterocyclic compounds as autotaxin inhibitors | MERCK PATENT GMBH (DE) | 2014-09-23 | — | — | US | claimed |
| US-20120015959-A1 | HETEROCYCLIC COMPOUNDS AS AUTOTAXIN INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-01-19 | — | — | US | claimed |
| EP-2414327-B1 | HETEROCYCLIC COMPOUNDS AS AUTOTAXIN INHIBITORS | MERCK PATENT GMBH (DE) | 2014-11-19 | — | — | EP | disclosed |
| US-8841324-B2 | Heterocyclic compounds as autotaxin inhibitors | MERCK PATENT GMBH (DE) | 2014-09-23 | — | — | US | disclosed |
| US-8841324-B2 | Heterocyclic compounds as autotaxin inhibitors | MERCK PATENT GMBH (DE) | 2014-09-23 | — | — | US | disclosed |
| US-8841324-B2 | Heterocyclic compounds as autotaxin inhibitors | MERCK PATENT GMBH (DE) | 2014-09-23 | — | — | US | disclosed |
| US-20120015959-A1 | HETEROCYCLIC COMPOUNDS AS AUTOTAXIN INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-01-19 | — | — | US | disclosed |
| US-20120015959-A1 | HETEROCYCLIC COMPOUNDS AS AUTOTAXIN INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-01-19 | — | — | US | disclosed |
| US-20120015959-A1 | HETEROCYCLIC COMPOUNDS AS AUTOTAXIN INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-01-19 | — | — | US | disclosed |
| WO-2010112116-A1 | HETEROCYCLIC COMPOUNDS AS AUTOTAXIN INHIBITORS | MERCK PATENT GMBH (DE) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015959-A1 | HETEROCYCLIC COMPOUNDS AS AUTOTAXIN INHIBITORS | ENPP2, HAX1, MTX1 | ENPP2 1/4885ATXN2 924/4885ALDH1A1 4564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.